Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

BACKGROUND: To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME) in the Greek setting. METHODS: A Markov model was adapted to compare the use of ranibizumab 0.5 mg (pro re nata-PRN and treat and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourlaba, Georgia, Relakis, John, Mahon, Ronan, Kalogeropoulou, Maria, Pantelopoulou, Georgia, Kousidou, Olga, Maniadakis, Nikos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831170/
https://www.ncbi.nlm.nih.gov/pubmed/27081372
http://dx.doi.org/10.1186/s12962-016-0056-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831170/
https://www.ncbi.nlm.nih.gov/pubmed/27081372
http://dx.doi.org/10.1186/s12962-016-0056-1

Ejemplares similares